



**UNITED STATES DEPARTMENT OF COMMERCE**  
**Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

*See*

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

08/653,294 05/24/96 CLAYBERGER

C 286002020023

KATE H MURASHIGE  
MORRISON & FOERSTER  
2000 PENNSYLVANIA AVENUE NW  
WASHINGTON DC 20006-1888

HM22/1101

EXAMINER

DIBRINO, M

ART UNIT

PAPER NUMBER

1644

DATE MAILED:

11/01/01

*47*

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). **A computer readable form (CRF) of the sequence listing was submitted. However, the CRF could not be processed by the Scientific and Technical Information Center (STIC) for the reason(s) set forth on the attached CRF Diskette Problem Report.**

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached CRF Diskette Problem Report with the reply.

Any inquiry concerning this communication should be directed to Examiner Ron Schwadron, Ph.D., Art Unit 1644, whose telephone number is (703) 308-4680. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

RONALD B. SCHWADRON  
PRIMARY EXAMINER  
GROUP 1800 *lcs*

Ron Schwadron, Ph.D.  
Art Unit 1644

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

RECEIVED

JUL 11 2001

# Raw Sequence Listing Error Summary

TECH CENTER 1600/2900

## ERROR DETECTED

## SUGGESTED CORRECTION

SERIAL NUMBER: 08/653,294B

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1        Wrapped Nucleics  
    Wrapped Aminos: The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
- 2        Invalid Line Length The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3        Misaligned Amino  
    Numbering The numbering under each 5<sup>th</sup> amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
- 4        Non-ASCII The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5        Variable Length Sequence(s)        contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6        PatentIn 2.0  
    "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s)       . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 7        Skipped Sequences  
    (OLD RULES) Sequence(s)        missing. If intentional, please insert the following lines for each skipped sequence:  
                  (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
                  (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)  
                  (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
                  This sequence is intentionally skipped  
  
                  Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
- 8        Skipped Sequences  
    (NEW RULES) Sequence(s)        missing. If intentional, please insert the following lines for each skipped sequence.  
                  <210> sequence id number  
                  <400> sequence id number  
                  000
- 9        Use of n's or Xaa's  
    (NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.  
                  Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.  
                  In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 10        Invalid <213>  
    Response Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
- 11        Use of <220> Sequence(s)        missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12        PatentIn 2.0  
    "bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

RECEIVED<sup>1644</sup>

JUL 11 2001

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/08/653,294B

DATE: 06/20/2001

TIME: 11:11:44

TECH CENTER 1600/2900

Input Set : D:\28600-20200.txt

Output Set: N:\CRF3\06202001\H653294B.raw

Does Not Comply  
Corrected Diskette Needed

3 <110> APPLICANT: Stanford University  
 4 Clayberger, Carol  
 5 Krensky, Alan  
 6 Buelow, Roland  
 8 <120> TITLE OF INVENTION: IMMUNOMODULATING DIMERS  
 11 <130> FILE REFERENCE: 28600-20200.23  
 13 <140> CURRENT APPLICATION NUMBER: 08/653,294B  
 14 <141> CURRENT FILING DATE: 1996-05-24  
 16 <150> PRIOR APPLICATION NUMBER: US 08/222,851  
 17 <151> PRIOR FILING DATE: 1994-04-05  
 19 <150> PRIOR APPLICATION NUMBER: US 07/844,716  
 20 <151> PRIOR FILING DATE: 1992-03-02  
 22 <150> PRIOR APPLICATION NUMBER: US 07/755,584  
 23 <151> PRIOR FILING DATE: 1991-09-03  
 25 <150> PRIOR APPLICATION NUMBER: US 07/672,147  
 26 <151> PRIOR FILING DATE: 1991-03-19  
 28 <150> PRIOR APPLICATION NUMBER: US 07/561,246  
 29 <151> PRIOR FILING DATE: 1990-07-30  
 31 <150> PRIOR APPLICATION NUMBER: US 07/008,846  
 32 <151> PRIOR FILING DATE: 1987-01-30  
 34 <160> NUMBER OF SEQ ID NOS: 42  
 36 <170> SOFTWARE: FastSEQ for Windows Version 4.0

pp 1-3

Please

consult

Sequence Rules,  
for valid  
format

## ERRORED SEQUENCES

38 <210> SEQ ID NO: 1  
 39 <211> LENGTH: 10  
 40 <212> TYPE: PRT  
 41 <213> ORGANISM: Human  
 43 <220> FEATURE:  
 44 <221> NAME/KEY: VARIANT Xaa at location 2  
 45 <222> LOCATION: (1)...(10) is  
 46 <223> OTHER INFORMATION: Xaa76 = E or V;  
 47 Xaa77 = D, S or N;  
 48 Xaa79 = R or G;  
 49 Xaa80 = I or N;  
 W--> 50 Xaa81 is a hydrophobic or small amino acid;  
 W--> 51 Xaa82 = R or L;  
 W--> 52 Xaa83 = G or R;  
 W--> 53 Xaa84 = is a hydrophobic or small amino acid.  
 55 <400> SEQUENCE 1  
 56 Arg Xaa76 Xaa77 Leu Xaa79 Xaa80 Xaa81 Xaa82 Xaa83 Xaa84  
 E--> 57 1 5 10  
 59 <210> SEQ ID NO: 2  
 60 <211> LENGTH: 10  
 61 <212> TYPE: PRT

Reword the statement:

Xaa at location 2

is

Per 1.823 of Sequence Rules,  
 the maximum number of  
 lines in <223> response is  
 4; insert a <220> after the  
 4th line and insert <223> at  
 beginning of 5th line

invalid - do not  
 insert numbers next to  
 Xaa's; just show  
 Xaa

misaligned amino  
 acid nos - see  
 item 3 on Error  
 Summary Sheet

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/08/653,294B

DATE: 06/20/2001

TIME: 11:11:44

Input Set : D:\28600-20200.txt

Output Set: N:\CRF3\06202001\H653294B.raw

RECEIVED

JUL 11 2001

TECH CENTER 1600/2900

62 <213> ORGANISM: Human  
 64 <220> FEATURE:  
 65 <221> NAME/KEY: VARIANT  
 66 <222> LOCATION: (1)...(10)  
 67 <223> OTHER INFORMATION: Xaa76 = E or V;  
 68 Xaa77 = D, S or N;  
 69 Xaa79 = R or G;  
 70 Xaa80 = I or N;  
 W--> 71 Xaa81 is a hydrophobic or small amino acid;  
 W--> 72 Xaa82 = R or L;  
 W--> 73 Xaa83 = G or R;  
 W--> 74 Xaa84 = is a hydrophobic or small amino acid.  
 76 <400> SEQUENCE: 2  
 E--> 77 Xaa84 Xaa83 Xaa82 Xaa81 Xaa80 Xaa79 Leu Xaa77 Xaa76 Arg  
 E--> 78 1 5 10 *misaligned nos.*  
 80 <210> SEQ ID NO: 3  
 81 <211> LENGTH: 10 *9 shown*  
 82 <212> TYPE: PRT  
 83 <213> ORGANISM: Human  
 85 <220> FEATURE:  
 86 <221> NAME/KEY: VARIANT  
 87 <222> LOCATION: (1)...(10)  
 88 <223> OTHER INFORMATION: Xaa1 = Any Amino Acid;  
 89 Xaa2 = N or I; or any amino acid of at least five carbon atoms;  
 90 Xaa3 = I or hydrophobic or small amino acid;  
 91 Xaa4 = R or any aliphatic amino acid of at least five carbon atoms;  
 W--> 92 Xaa5 = G or R or any aliphatic amino acid;  
 W--> 93 Xaa6 = any amino acid, hydrophobic or small.  
 95 <400> SEQUENCE: 3  
 96 Arg Glu Xaa1 Leu Arg Xaa2 Xaa3 Xaa4 Xaa5  
 E--> 97 1 5 10  
 433 <210> SEQ ID NO: 38  
 434 <211> LENGTH: 10  
 435 <212> TYPE: PRT  
 436 <213> ORGANISM: Human  
 438 <220> FEATURE:  
 439 <221> NAME/KEY: VARIANT  
 440 <222> LOCATION: (1)...(10)  
 441 <223> OTHER INFORMATION: Xaa77 = D, S or N;  
 442 Xaa80 = I or N;  
 443 Xaa81 = A or L;  
 444 Xaa82 = R or L;  
 W--> 445 Xaa83 = G or R.  
 447 <400> SEQUENCE: 38  
 E--> 448 Arg Glu Xaa77 Leu Arg Xaa80 Xaa81 Xaa82 Xaa83 Tyr.  
 E--> 449 1 5 10 *misaligned nos.*  
 451 <210> SEQ ID NO: 39  
 452 <211> LENGTH: 10  
 453 <212> TYPE: PRT

*same error**same error**same error*

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/08/653,294B

DATE: 06/20/2001

TIME: 11:11:44

Input Set : D:\28600-20200.txt

Output Set: N:\CRF3\06202001\H653294B.raw

454 <213> ORGANISM: Human  
456 <220> FEATURE:  
457 <221> NAME/KEY: VARIANT  
458 <222> LOCATION: (1)...(10)  
459 <223> OTHER INFORMATION: Xaa77 = D,S or N;  
460 Xaa80 = I or N;  
461 Xaa81 = A or L;  
462 Xaa82 = R or L;  
W--> 463 Xaa83 = G or R.  
465 <400> SEQUENCE: 39  
E--> 466 Tyr Xaa83 Xaa82 Xaa81 Xaa80 Arg Leu Xaa77 Glu Arg ,  
E--> 467 1 5 10

## VERIFICATION SUMMARY

DATE: 06/20/2001

PATENT APPLICATION: US/08/653,294B

TIME: 11:11:45

Input Set : D:\28600-20200.txt

Output Set: N:\CRF3\06202001\H653294B.raw

L:50 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:51 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:52 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:53 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:57 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:1  
L:57 M:252 E: No. of Seq. differs, <211>LENGTH:Input:10 Found:0 SEQ:1  
L:71 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:72 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:73 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:74 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:77 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2  
L:77 M:333 E: Wrong sequence grouping, Amino acids not in groups!  
L:77 M:320 E: (1) Wrong Nucleic Acid Designator, NUMBER OF INVALID KEYS:8  
L:78 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:2  
L:92 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:93 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:97 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:3  
L:97 M:252 E: No. of Seq. differs, <211>LENGTH:Input:10 Found:0 SEQ:3  
L:245 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19  
L:259 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20  
L:445 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:448 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38  
L:448 M:333 E: Wrong sequence grouping, Amino acids not in groups!  
L:448 M:320 E: (1) Wrong Nucleic Acid Designator, NUMBER OF INVALID KEYS:5  
L:449 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:38  
L:463 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:466 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:39  
L:466 M:333 E: Wrong sequence grouping, Amino acids not in groups!  
L:466 M:320 E: (1) Wrong Nucleic Acid Designator, NUMBER OF INVALID KEYS:5  
L:467 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:39